2026-01-23 - Analysis Report
**Company Overview**
Align Technology is a medical device company that specializes in the design, manufacturing, and marketing of clear aligner therapy for people with malocclusion.

**Return Rate Comparison**
| Ticker | Cumulative Return |
| --- | --- |
| ALGN (Review Stock) | -47.73% |
| VOO (Comparison Stock: S&P 500) | 92.53% |
| Divergence | -140.20 |
| Relative Divergence | 4.20% |

The cumulative return of ALGN is significantly lower than the S&P 500, indicating a divergence of -140.20. This represents a 4.20% relative divergence, which is at the lower end of the 0-100% fluctuation range.

**Alpha, Beta Analysis**
| Period | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 47.0% | 48.8% | 42.0% | 1.5 | 15.2B |
| 2017-2019 | 69.0% | 50.2% | 51.0% | 1.6 | 20.2B |
| 2018-2020 | -23.0% | 50.2% | -44.0% | 1.5 | 38.7B |
| 2019-2021 | 16.0% | 45.1% | -28.0% | 1.5 | 47.6B |
| 2020-2022 | -108.0% | 75.2% | -106.0% | 1.5 | 15.3B |
| 2021-2023 | -138.0% | 75.2% | -139.0% | 1.7 | 19.9B |
| 2022-2024 | -79.0% | 64.3% | -99.0% | 1.7 | 15.1B |
| 2023-2025 | -25.0% | 57.2% | -87.0% | 1.5 | 11.3B |

The Alpha and Beta values for each period indicate varying degrees of market outperformance and volatility.

**Recent Stock Price Fluctuations**
| Figure | Value |
| --- | --- |
| Close | $168.92 |
| Last Market | -0.61% |
| 5-day SMA | $169.48 |
| 20-day SMA | $164.90 |
| 60-day SMA | $152.62 |

The stock price has shown a slight decline in the last market day, with the 20-day SMA and 60-day SMA indicating possible support levels.

**RSI, PPO, and Delta_Previous_Relative_Divergence Analysis**
| Indicator | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.90 |
| RSI | 67.85 |
| PPO | -0.26 |
| Hybrid Signal | Buy |
| Risk Level | High |
| Recent Relative Divergence Change | 0.10 (+) |
| 7-day Rank Change | 57 (+) |
| 7-day Dynamic Expected Return Change | -0.90 (-) |

The RSI and PPO indicators suggest possible overbought conditions, while the Market Risk Indicator indicates a high risk level.

**Expected Return**
-1656.90% expected excess return compared to the S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events**

* [2026-01-22] Assessing Align Technology (ALGN) Valuation After Recent Share Price Momentum And Mixed Signals - Yahoo Finance
* [2026-01-22] Align Expands Invisalign To Thailand As Analysts Reassess ALGN Outlook
* [2026-01-20] Mizuho Maintains "Outperform" Rating for ALGN, Raises Price Target
* [2026-01-21] Align Tech (ALGN) Receives a Hold from UBS
* [2025-10-30] Why Align Technology Stock Popped Today
* [2025-10-30] Align Technology Stock Forecast: Where Analysts See the Stock by 2027

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.17 (~Buy)
- Opinions: 15
- Target Price (avg/high/low): 182.47 / 220.00 / 150.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-11-05 | $0.78 | $1.00B |
| 2025-08-06 | $1.72 | $1.01B |
| 2025-05-08 | $1.27 | $0.98B |
| 2024-11-05 | $1.55 | $0.98B |

The earnings per share (EPS) has been declining, while the revenue remains relatively stable.

**Financial Information**

**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $1.00B | 64.20% |
| 2025-06-30 | $1.01B | 69.94% |
| 2025-03-31 | $0.98B | 69.45% |
| 2024-12-31 | $1.00B | 70.03% |
| 2024-09-30 | $0.98B | 69.72% |

The profit margin has shown a slight decline.

**Capital and Profitability**
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $3.96B | 1.43% |
| 2025-06-30 | $3.91B | 3.18% |
| 2025-03-31 | $3.79B | 2.46% |
| 2024-12-31 | $3.85B | 2.69% |
| 2024-09-30 | $3.94B | 2.94% |

The ROE has shown a decline in the last two quarters.

**Comprehensive Analysis (Summary of previous items)**

Align Technology's performance has been marred by a decline in EPS, while the revenue remains relatively stable. The stock price has shown a slight decline, with the 20-day SMA and 60-day SMA indicating possible support levels. The RSI and PPO indicators suggest possible overbought conditions, while the Market Risk Indicator indicates a high risk level. The expected return is negative, indicating a possible long-term underperformance compared to the S&P 500.

The earnings analysis and financial information tables suggest a stable revenue but declining profit margin, while the capital and profitability analysis indicate a decline in ROE. The comprehensive analysis is mixed, indicating caution when investing in Align Technology.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.